Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from PAVmed ( (PAVM) ) is now available.
On March 30, 2026, PAVmed reported fourth-quarter and full-year 2025 results, highlighting major balance sheet repairs and a relaunch of its medical device portfolio under new leadership. The company completed a $30 million Series D preferred stock offering and a $15 million senior secured note financing, used part of the proceeds to retire all outstanding convertible securities, modestly increased year-end cash to $1.5 million, and reported a GAAP net loss of $1.8 million and a non-GAAP adjusted loss of $0.9 million for the quarter.
Operationally, Veris Health advanced its commercial rollout with Ohio State University’s James Cancer Hospital, fully integrating into its electronic health record system and moving its implantable physiological monitor toward a planned late-2026 FDA 510(k) submission. Lucid Diagnostics grew its EsoGuard franchise, generating $1.5 million in fourth-quarter 2025 revenue from 3,664 tests, securing a U.S. Department of Veterans Affairs contract to broaden access, and releasing positive real-world data from nearly 12,000 at-risk patients, developments that strengthen PAVmed’s competitive position and support potential future coverage and adoption of its technologies.
The most recent analyst rating on (PAVM) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on PAVmed stock, see the PAVM Stock Forecast page.
Spark’s Take on PAVM Stock
According to Spark, TipRanks’ AI Analyst, PAVM is a Neutral.
The score is constrained primarily by weak financial quality (large losses, negative gross profit, and persistent cash burn). Technicals also remain bearish with the stock trading below key moving averages and negative MACD. Offsetting support comes from a more constructive earnings update (potential near-term Medicare coverage, funding runway through 2026) and corporate actions that improve capital structure and listing stability, but these do not yet outweigh the underlying profitability and cash-flow risks.
To see Spark’s full report on PAVM stock, click here.
More about PAVmed
PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, with subsidiaries Lucid Diagnostics and Veris Health. Its portfolio includes the EsoGuard Esophageal DNA Test, the EsoCheck cell collection device, the PortIO implantable intraosseous vascular access device, and an implantable physiological monitor, with a market focus on early cancer detection and advanced patient monitoring.
The company is repositioning itself as a high-growth, multi-subsidiary life sciences platform, using a shared services model to support independently financed businesses. Under new leadership, it has relaunched its medical device portfolio and licensed endoscopic esophageal imaging technology from Duke University, adding another potential growth engine and reinforcing its presence in gastroesophageal disease diagnostics and intervention.
Average Trading Volume: 1,040,086
Technical Sentiment Signal: Strong Sell
Current Market Cap: $12.98M
Find detailed analytics on PAVM stock on TipRanks’ Stock Analysis page.